Michael Deyoung, DO
Cardiovascular Disease · Mount Clemens, MINPI 1487861043
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (47.7%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. 40 manufacturers reported payments, led by Abbott at 55.1% of the total. Among cardiovascular disease clinicians in MI with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 446 payments — averaging $155.18 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$38K
- Cardiovascular Systems Inc.$12K
- Medtronic$9K
- Boston Scientific$2K
- Abiomed$2K
- Novartis$694
- plus $5K from 34 others
Across 1 payment — averaging $7982.98 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AstraZeneca$8K
What the payments were for
- Consulting fees$10,75016%
- Speaking & faculty fees$33,02048%
- Travel & lodging$12,59818%
- Food & beverage$12,64418%
- Education$2000%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Diamondback Coronary$16,012
- XIENCE SIERRA$8,139
- Dragonfly OCT$7,500
- DRAGONFLY OPSTAR$7,382
- Xience V coronary stent system$4,000
- COROFLOW$2,500
- ACCULINK$1,057
- OPTIS$1,000
- MO.MA ULTRA$784
- Watchman$731
- SYMPLICITY G3$652
- FLOWTRIEVER CATHETER, S$318
- CT THROMBECTOMY SYSTEM KIT$318
- Indigo System$284
- ELUVIA$270
- WATCHMAN Access System$266
- Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter$266
- Assure WCD$226
- AVEIR$176
- Diamondback Peripheral$160
How this compares
$69,212 in reported general payments places this provider in the 90th percentile of 760 cardiovascular disease providers in Michigan.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 392 | $494,949 |
| XareltoRivaroxaban | 103 | $153,923 |
| EntrestoSacubitril/Valsartan | 73 | $115,089 |
| FarxigaDapagliflozin Propanediol | 45 | $53,744 |
| Repatha SureclickEvolocumab | 37 | $40,435 |
| BrilintaTicagrelor | 38 | $37,080 |
| JardianceEmpagliflozin | 26 | $31,269 |
| Praluent PenAlirocumab | 20 | $16,271 |
| Ranolazine ErRanolazine | 37 | $6,944 |
| Atorvastatin Calcium | 390 | $6,801 |
| ClopidogrelClopidogrel Bisulfate | 301 | $6,649 |
| Metoprolol Succinate | 324 | $5,820 |
| Carvedilol | 276 | $4,313 |
| Losartan Potassium | 245 | $3,504 |
| Propafenone Hcl | 29 | $3,499 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $255 | $494,949392 claims |
| Johnson & JohnsonXarelto | $367 | $153,923103 claims |
| NovartisEntresto | $694 | $115,08973 claims |
| AstraZenecaFarxiga, Brilinta | $181 | $90,82483 claims |
| Boehringer IngelheimJardiance | $118 | $31,26926 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 760 cardiovascular disease providers in Michigan.
Other cardiovascular disease in Mount Clemens
- Timothy LoganMount Clemens$61K
- Marschall RungeAnn Arbor$1.8M
- Jihad MustaphaGrand Rapids$1.6M
- Vallerie McLaughlinAnn Arbor$947K
- Pedro Villablanca SpinettoDetroit$620K
- Stanley ChetcutiAnn Arbor$573K
- David HainesRoyal Oak$492K
- Steven AlmanyTroy$471K
- David StroblLansing$445K
- Herman KadoSouthfield$442K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.